EcoDrugPlus

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSCGOG00000020598
Gene Symbol: AGTR1
3 Cross references
203 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSCGOG00000024232
Gene Symbol: AGTR2
1 Cross references
189 Possible Orthologues:

Apelin Receptor A-Like

Ensembl ID : ENSCGOG00000022482
Gene Symbol: LOC115009430
3 Cross references
172 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSCGOG00000022098
Gene Symbol: APEX1
3 Cross references
214 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSCGOG00000015424
Gene Symbol: ALOX5
3 Cross references
212 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSCGOG00000023895
Gene Symbol: ALOX5AP
3 Cross references
201 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Like

Ensembl ID : ENSCGOG00000011479
Gene Symbol: LOC115023433
3 Cross references
200 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSCGOG00000005157
Gene Symbol: AVPR1A
3 Cross references
186 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSCGOG00000024201
Gene Symbol: AVPR1A
3 Cross references
203 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSCGOG00000012611
Gene Symbol: AVPR2
3 Cross references
166 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSCGOG00000013937
Gene Symbol: AVPR2
3 Cross references
210 Possible Orthologues:

Aromatase

Ensembl ID : ENSCGOG00000017219
Gene Symbol: LOC115024369
3 Cross references
252 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).